NATCO announces launch of its Everolimus tablets, 1 mg, (generic of Zortress®)

NATCO Pharma Limited (BSE: 524816 and NSE: NATCOPHARM) ("NATCO") announces launch of Everolimus tablets 1mg, a generic version of Zortress® by Novartis, under the therapeutic class of immunosuppressant. NATCO's marketing partner for the ANDA, Breckenridge Pharmaceutical, Inc., the U.S. subsidiary of Towa International, plans to launch the product immediately in the U.S. market.

Everolimus is an mTOR inhibitor immunosuppressant indicated for the prophylaxis of organ rejection in adult patients in kidney and liver transplantation.

Breckenridge previously launched its Everolimus Tablets in 0.25mg, 0.5mg, and 0.75mg strengths, with blisters launched in July 2021 and bottles launched in June 2023.

Shares of Natco Pharma Limited was last trading in BSE at Rs. 833.15 as compared to the previous close of Rs. 828.45. The total number of shares traded during the day was 33105 in over 3067 trades.

The stock hit an intraday high of Rs. 835.30 and intraday low of 824.40. The net turnover during the day was Rs. 27402098.00.

Source : Equity Bulls

Keywords

NatcoPharma INE987B01026 Pharmaceuticals EverolimusTablets Launch